RSS Activity Directors and Planning Committee Members Disclosure for 2024

For 2024, the following RSS Activity Directors and Planning Committee Members have disclosed relationships with ineligible companies**

Disclosure Statement

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education anyone involved in planning or presenting this educational activity will be required to disclose any financial relationships with any ineligible companies. An ineligible company is any entity whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.  Any financial relationships with these ineligible companies have been mitigated by the MUSC Office of CME. Speakers who incorporate information about off-label or investigational use of drugs or devices will be asked to disclose that information at the beginning of their presentation. 

The following information has been disclosed for 2024:

Barry Gibney, M.D. is the activity director for the 2024 Cardiothoracic Surgery TSDA & M&M. Dr. Gibney has disclosed the following: Consultant with Intuitive Surgical. 

Mark Katz, M.D. is on the planning committee for the 2024 Cardiothoracic Surgery TSDA & M&M. Dr. Katz has disclosed the following: Consultant with Abbott Vascular, Boston Scientific, Edwards, and Medtronic. 

Jacqueline Kraveka, D.O. is the activity director for the 2024 Pediatric Tumor Board. Dr. Kraveka has disclosed the following: Consultant with Y-mAbs Therapeutics and US WorldMeds. 

Scott Lindhorst, M.D. is the activity director for the 2024 Neuro Tumor Board. Dr. Lindhorst has disclosed the following: Consultant with Ono Pharma*

Nicholas Pope, M.D. is on the planning committee for the 2024 Cardiothoracic Surgery TSDA & M&M. Dr. Pope has disclosed the following: Consultant with Abbott Vascular and Alexion Pharmaceuticals.

Don Rockey, M.D. is the activity director for the 2024 GI Grand Round. Dr. Rocky has disclosed the following: Consultant with Calliditas Therapeutics, Takeda, and Xeris Pharmaceuticals; Advisory Board for AstraZeneca, Resolution Therapeutics, Takeda; Research with AstraZeneca, Axella Therapeutics*, Bio89, Boehringer Ingelheim, Durect*, Galectin Therapeutics, Gilead Sciences, Helio*, Intercept Pharmaceuticals, Ipsen, Inventiva Pharma*, Madrigal, Novo Nordisk, Ocelot Biological*, Pfizer*, Salix Pharmaceuticals

Ryan Tedford, M.D. is the activity director for the 2024 Heart Failure Noon Conference.  Dr. Tedford has disclosed the following: Consultant with Abbott, Acorai, Aria CV, Merck, Alleviant*, Boston Scientific, Cytokinetics, Edwards LifeSciences, Gradient, Lexicon*, Medtronic, and United Therapeutics; Stock options with Aria CV; Core Lab with Merck; Steering Committee with Merck, Edwards LifeSciences, and Gradient; Research Advisory Board with Abiomed

*The relationship has ended in the last 24 months

**An ineligible company is a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.